Effect of nucleosid analog and peginterferon alfa 2a sequential therapy on patients with chronic hepatitis B

Effect of nucleosid analog and peginterferon alfa 2a sequential therapy on patients with chronic hepatitis B - Sequential therapy with chronic hepatitis B

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000013811

Enrollment

Registered

2014-05-01

Start date

2012-04-27

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic hepatitis B

Interventions

peginterferon-alpha2a entecavir adefovir dipivoxil lamivudine

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patient who the nucleic acid analog tablet for 48 or more weeks (entecavir Adefovir dipivoxil,Lamivudinele) is having medication continued, and presents HBV DNA negativity(less than 2.6 log copy/mL) to B type chronic hepatitis

Exclusion criteria

Exclusion criteria: 1) Patients receiving Chinese herb (sho-sai-ko-to) 2) Patients with history of interstitial pneumonia 3) Patients with auto immune hepatitis 4) Patients with hypersensitivity to interferon 5) Patients with hypersensitivity to biological agents 6) Patients with neutropenia (<1500/mm3), thrombocytopenia (<90000/mm3), or anemia (Hb<12g/dL) 7) Cirrhotic patients 8) Patients with history of HCC 9) Doctors consider inadequate

Design outcomes

Primary

Measure	Time frame
drug free ALT<40 HBV-DNA<5.0Log/ml	—

Countries

Japan

Contacts

Public ContactMiwa Kawanaka

Kawasaki Medical school General Internal Medicine2

m.kawanaka@med.kawasaki-m.ac.jp086-225-2111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026